ANGLE presents two posters at EACR

PARSORTIX-BASED ASSAYS SHOWCASED AT THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH LIQUID BIOPSIES CONFERENCE

Two posters highlight the importance of epitope-independent CTC enrichment and molecular characterisation of CTCs

GUILDFORD, SURREY / ACCESSWIRE / November 13, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce its participation at the European Association for Cancer Research (EACR) Liquid Biopsies Conference being held in Lyon, France from 12 to 14 November 2024.

ANGLE presented two posters at the EACR Liquid Biopsies Conference:

1. Combined epitope-independent microfluidic isolation and advanced staining of circulating tumour cells isolated from metastatic prostate cancer blood samples

This poster presentation reports on the utility of combining ANGLE’s Parsortix^® system for CTC capture with the Portrait^®+ CTC staining kit for CTC detection and phenotypic characterisation. This workflow provides an efficient, standardised solution for the characterisation of multiple CTC phenotypes (epithelial, mesenchymal and those transitioning).

In a cohort of prostate cancer patients 64% of patients were positive for CTCs, and CTC clusters, which have up to 100 times increased metastatic potential, were found in 67% of the CTC positive samples. Patients with only mesenchymal CTCs accounted for 77% of the CTC positive patients, and no patients had only epithelial CTCs. This highlights the importance and value of using an epitope-independent CTC enrichment system, such as the Parsortix system.

This study also demonstrates the potential utility of this workflow for longitudinal patient monitoring, where changes in CTC number (including their absence) and phenotype are associated with patient status. The study presented two case studies of metastatic prostate cancer patients with CTC results preceding a change in patient clinical status over time.

2. Enhancing Multiplexing Capabilities in Digital PCR for Circulating Tumour Cell Analysis Using Amplitude-Based methodology

Molecular characterisation of CTCs is particularly important in the metastatic disease setting, where tissue biopsies may not be possible or repeatable, and there is a need for real-time tumour analysis and longitudinal monitoring of disease progression and treatment response. Recent advances in digital PCR (dPCR) technology, combined with multiplexing capabilities, have enhanced the ability to perform precise molecular characterisation from even a small number of CTCs.

This proof-of-concept study demonstrates that using amplitude-based multiplexing with QIAGEN’s Qiacuity dPCR system can increase the number of genes that can be assessed simultaneously in a Parsortix-enriched CTC sample. This method of molecular characterisation improves the ability to report a wider range of genetic markers from a single sample with the potential to provide a more comprehensive view into tumour biology.

Chief Scientific Officer, Karen Miller, commented:
“We are pleased to have presented two posters at the EACR Liquid Biopsies Conference. The results of these studies further demonstrate the utility of ANGLE’s technology for capturing and characterising CTCs at both the cellular and molecular level. Advances in molecular characterisation will be key to building a comprehensive picture of cancer and providing insight during targeted drug discovery and development. We are continuing to develop Parsortix-based molecular assays to provide a range of highly sensitive and specific assays to serve the needs of our pharma customers.”

The posters are available for review at: https://angleplc.com/resources/posters/

For further information:

For Research Use Only. Not for use in diagnostic procedures.

For Frequently Used Terms, please see the Company’s website on https://angleplc.com/investor-relations/glossary/

About ANGLE plc

ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE’s FDA cleared and patent protected CTC harvesting technology known as the Parsortix^® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.

ANGLE’s commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE’s GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays.

Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com

Any reference to regulatory authorisations such as FDA clearance, CE marking or UK MHRA registration shall be read in conjunction with the full intended use of the product:

The Parsortix^® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K₂EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions.

All results reported in this announcement and any other products and services are for research use only and not for use in diagnostic procedures.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: ANGLE plc

View the original press release on accesswire.com